Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Hao Lin,Chaxian Liu,Ankang Hu,Duanwu Zhang,Hui Yang,Ying Mao

DOI: https://doi.org/10.1186/s13045-024-01544-7

IF: 28.5

2024-05-11

Journal of Hematology & Oncology

Abstract:Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45 + cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.

oncology,hematology

What problem does this paper attempt to address?

The paper aims to explore the mechanisms of the immunosuppressive microenvironment in glioblastoma (GBM) and provide new insights from a clinical perspective. GBM is a major primary malignant intracranial tumor that poses significant challenges to traditional treatments due to its immunosuppressive microenvironment. Although current treatment methods include surgery, radiotherapy, temozolomide chemotherapy, as well as emerging immunotherapies and medical-engineering combined technologies, their effectiveness remains limited, leading to poor prognosis.

In recent years, research on the inhibitory and immunosuppressive microenvironment in GBM has deepened, emphasizing the importance of cellular components in the GBM microenvironment and their interactions with malignant cells and neurons. New immunotherapy and targeted therapy strategies are continuously emerging, offering hope for improving GBM treatment. Among these, myeloid-derived suppressor cells (MDSCs), glioma-associated macrophages/microglia (GAM), and regulatory T cells (Tregs) play key roles in GBM immunosuppression. Particularly, MDSCs, although accounting for only 4-8% of CD45+ cells in GBM, play a central role in promoting immune evasion, tumor progression, angiogenesis, invasion, and metastasis.

The paper aims to provide a theoretical basis for intervening in GBM immunosuppression by reviewing the immunoregulatory mechanisms of GBM, existing therapeutic targets, and the latest research on MDSC induction and its contribution to GBM immunosuppression. Additionally, the paper comprehensively reviews ongoing clinical trials and potential therapeutic strategies, envisioning the future prospects of reshaping the GBM immune landscape by targeting MDSCs. By synergistically integrating immunotherapy with other treatment modalities, this approach is expected to establish a multidisciplinary, multi-target therapeutic paradigm, ultimately improving the prognosis and quality of life for GBM patients.